Metabolic targets of cardiac hormones' therapeutic anti-cancer effects

Current Pharmaceutical Design

Volumn 16, Issue 9, 2010, Pages 1159-1166

  Vesely, David L ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cancer; Metastasis; Natriuretic peptides

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; KALIURETIC PEPTIDE; LONG ACTING NATRIURETIC PEPTIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MYC PROTEIN; NATRIURETIC PEPTIDE TYPE C; PEPTIDE HORMONE; PLATELET DERIVED GROWTH FACTOR; PROTEIN C FOS; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG; URODILATIN; VASCULOTROPIN; VESSEL DILATOR PEPTIDE;

ANTINEOPLASTIC ACTIVITY; BREAST ADENOCARCINOMA; BREAST CARCINOMA; CANCER SURVIVAL; CELL NUCLEUS; COLON CARCINOMA; DNA SYNTHESIS INHIBITION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; FIBROBLAST; HEART; HUMAN; IMMUNOFLUORESCENCE; IN VIVO STUDY; KIDNEY CARCINOMA; LUNG SMALL CELL CANCER; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ATRIAL NATRIURETIC FACTOR; CELL NUCLEUS; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MODELS, BIOLOGICAL; MYOCARDIUM; NEOPLASMS; RECEPTORS, ATRIAL NATRIURETIC FACTOR; SIGNAL TRANSDUCTION;

EID: 77950200129     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790963887     Document Type: Review

References (89)

1. Brenner BM, Ballermann BJ, Gunning ME, Ziedel ML. Diverse biological actions of atrial natriuretic peptide. Physiol Rev 1990; 70: 665-699
2. Gardner DG, Kovacic-Milivojevic BK, Garmai M. Molecular biology of the natriuretic peptides. In: Vesely DL, Ed. Atrial Natriuretic Peptides. Trivandrum, India: Research Signpost 1997; pp. 15-38.
3. th ed. San Diego, CA: Elsevier/Academic Press 2007; pp. 947-977.
4. 2-terminus are natriuretic and/or kaliuretic. Am J Physiol 1990; 258: F1401-F8.
5. 2. J Clin Invest 1992; 89: 1411-1417
6. Benjamin BA, Peterson TV. Effects of proANF (31-67) on sodium excretion in conscious monkeys. Am J Physiol 1995; 269: R1351-R5.
7. + reabsorption by ANP 31-67. Clin Exp Pharmacol Physiol 1995; 22: 121-124
8. Villarreal D, Reams GP, Taraben A, Freeman RH. Hemodynamic and renal effects of proANF 31-67 in hypertensive rats. Proc Soc Exp Biol Med 1999; 221: 166-170
9. Dietz JR, Scott DY, Landon CS, Nazian SJ. Evidence supporting a physiological role for proANP (1-30) in the regulation of renal excretion. Am J Physiol 2001; 280: R1510-R7.
10. Vesely DL, Douglass MA, Dietz JR, Gower WR Jr, McCormick MT, Rodriguez-Paz G, et al. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis and/or kaliuresis in humans. Circulation 1994; 90: 1129-1140
11. Vesely DL, Douglass MA, Dietz JR, Gower WR Jr, McCormick MT, Rodriguez-Paz G, et al. Negative feedback of atrial natriuretic peptides. J Clin Endocrinol Metab 1994; 78: 1128-1134
12. Vesely DL, Dietz JR, Parks JR, Baig M, McCormick MT, Cintron G, et al. Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation 1998; 98: 323-329
13. Vesely DL. Atrial Natriuretic Hormones. Englewood Cliffs, NJ: Prentice Hall 1992; pp. 1-256.
14. Vesely DL. Atrial natriuretic peptide prohormone gene expression: Hormones and diseases that upregulate its expression. IUBMB Life 2002; 53: 153-159
15. Lainchbury J, Richards AM, Nicholls MG. Brain natriuretic peptide in heart failure. In: Vesely DL, Ed. Atrial Natriuretic Peptides. Trivandrum, India: Research Signpost 1997; pp. 151-158.
16. Scotland RS, Ahluwalia A, Hobbs AJ. C-type natriuretic peptide in vascular physiology and disease. Pharmacol Ther 2005; 105: 85-93.
17. Cataliotti A, Burnett JC, Jr. Natriuretic peptides: novel therapeutic targets in heart failure. J Invest Med 2005; 53: 378-384
18. Winters CJ, Sallman AL, Baker BJ, Meadows JJ, Rice DM, Vesely DL. The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation 1989; 80: 438-449
19. Vesely DL, Norsk P, Winters CJ, Rico DM, Sallman AL, Epstein M. Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans. Proc Soc Exp Biol Med 1989; 192: 230-235
20. Hunter EFM, Kelly PA, Prowse C, Woods FJ, Lowry PJ. Analysis of peptides derived from pro atrial natriuretic peptide that circulate in man and increase in heart disease. Scan J Clin Lab Invest 1998; 58: 205-216
21. De Palo EF, Woloszczuk W, Meneghetti M, DePalo CB, Nielsen HB, Secher NH. Circulating immunoreactive proANP (1-30) and proANP (31-67) in sedentary subjects and athletes. Clin Chem 2000; 46: 843-847
22. Franz M, Woloszczuk W, Horl WH. N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment. Kidney Int 2000; 58: 374-378
23. Franz M, Woloszczuk W, Horl WH. Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney disease. Kidney Int 2001; 59: 1928-1934
24. Toshimori H, Toshimori K, Oura C, Matsuo H. Immunohisto-chemical study of atrial natriuretic polypeptides in the embryonic fetal and neonatal rat heart. Cell Tissue Res 1987; 248: 627-633
25. Abell TJ, Richards AM, Ikram H, Espiner EA, Yandle T. Atrial natriuretic factor inhibits proliferation of vascular smooth muscle cells stimulated by platelet derived growth factor. Biochem Biophys Res Commun 1989; 160: 1392-1396
26. Itoh H, Pratt RE, Dzau VJ. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 1990; 86: 1690-1697
27. Itoh H, Pratt TE, Ohno M, Dzau VJ. Atrial natriuretic polypeptide as a novel antigrowth factor of endothelial cells. Hypertension 1992; 19: 758-761
28. Johnson A, Lermioglu F, Garg UC, Morgan-Boyd R, Hassid A. A novel biological effect of atrial natriuretic hormone: inhibition of mesangial cell mitogenesis. Biochem Biophys Res Commun 1988; 152: 893-897
29. Appel RG. Growth inhibitory activity of atrial natriuretic factor in rat glomerular mesangial cells. FEBS Lett 1988; 238: 135-138
30. Appel RG. Mechanism of atrial natriuretic factor-induced inhibition of rat mesangial cell mitogenesis. Am J Physiol 1990; 259: E312-E8.
31. Appel RG. Growth-regulatory properties of atrial natriuretic factor. Am J Physiol 1992; 262: F911-F8.
32. Haneda M, Kikkawa R, Koya D, Sakamoto K, Nakanishi S, Matsuda Y, et al. Biological receptors mediate anti-proliferative action of atrial natriuretic peptide in cultured mesangial cells. Biochem Biophys Res Commun 1993; 192: 642-648
33. Pedram A, Razandi M, Hu RM, Levin ER. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem 1997; 272: 17097-17103
34. Yu SM, Hung LM, Lin CC. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibition of the activation of epidermal growth factor signaling pathway. Circulation 1997; 95: 1269-1277
35. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998; 101: 812-818
36. Vesely BA, McAfee Q, Gower WR, Jr, Vesely DL. Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest 2003; 33: 998-1005.
37. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Solivan SR, Gower WR, Jr, et al. Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur J Clin Invest 2005; 35: 60-69
38. Vesely BA, Alli AA, Song S, Gower WR, Jr, Sanchez-Ramos J, Vesely DL. Four peptide hormones specific decrease (up to 97%) of human prostate carcinoma cells. Eur J Clin Invest 2005; 35: 700-710
39. Gower WR, Jr, Vesely BA, Alli AA, Vesely DL. Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via guanosine 3',5'-cyclic mmonophosphate. Int J Gastrointestinal Cancer 2006; 36: 77-87.
40. Vesely BA, Eichelbaum EJ, Alli AA, Sun Y, Gower WR, Jr, Vesely DL. Urodilatin and four cardiac hormones decrease human renal carcinoma cell number. Eur J Clin Invest 2006; 36: 810-819
41. Vesely BA, Eichelbaum EJ, Alli AA, Sun Y, Gower WR, Jr, Vesely DL. Four cardiac hormones cause cell death in 81% of human ovarian adenocarcinoma cells. Cancer Therapy 2007; 5: 97-104.
42. Vesely BA, Alli A, Song S, Sanchez-Ramos J, Fitz SR, Gower WR, Jr, et al. Primary malignant tumors of the heart: Four cardiovascular hormones decrease the number and DNA synthesis of human angiosarcoma cells. Cardiology 2006; 105: 226-233
43. Vesely BA, Eichelbaum EJ, Alli AA, Sun Y, Gower WR, Jr, Vesely DL. Four cardiac hormones cause cell death of melanoma cells and inhibit their DNA synthesis. Am J Med Sci 2007; 334: 342-349
44. Eichelbaum EJ, Vesely BA, Alli AA, Sun Y, Gower WR, Jr,Vesely DL. Four cardiac hormones decrease up to 82% of human medullary thyroid carcinoma cells within 24 hours. Endocrine 2006; 30: 325-332
45. Vesely BA, Eichelbaum EJ, Alli AA, Sun Y, Gower WR, Jr, Vesely DL. Four cardiac hormones eliminate 4-fold more human glioblastoma cells than green mamba snake peptide. Cancer Lett 2007; 254: 94-101.
46. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Gower WR, Jr, Vesely DL. Five cardiac hormones decrease the number of human small-cell cancer cells. Eur J Clin Invest 2005; 35: 388-398
47. Vesely BA, Fitz SR, Gower WR, Jr, Vesely DL. Vessel dilator: Most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of squamous lung cancer cells. Cancer Lett 2006; 233: 226-231
48. Schulz-Knappe P, Forssmann K, Herbst F, Hock D, Pipkorn R, Forsmann WF. Isolation and structural analysis of 'urodilatin', a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr 1988; 66: 752-759
49. Vesely DL. Which of the cardiac natriuretic peptides is the most effective for the treatment of congestive heart failure, renal failure, and cancer? Clin Exp Pharmacol Physiol 2006; 33: 169-176
50. rd ed. Baltimore, MD: Williams & Wilkins 1995; pp. 227-231.
51. Suga SI, Nakao K, Hosoda K, Mukoyama M, Ogawa Y, Shirakami G, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 1992; 130: 229-239
52. Heim JM, Kiefersauer S, Fülle HJ, Gerzer R. Urodilatin and beta-ANF: binding properties and activation of particulate guanylate cyclase. Biochem Biophys Res Commun 1992; 163: 37-41.
53. Saxenhofer H, Fitzgibbon W, Paul RV. Plasma levels and dialysance of atrial natriuretic peptide in terminal renal failure. Kidney Int 1987; 32: 554-561
54. Valentin JP, Sechi LA, Qui C, Schambelan M, Humphrey MH. Urodilatin binds to and activates renal receptors for atrial natriuretic peptide. Hypertension 1993; 21: 432-438
55. Pitchumoni CS. Pancreatic Disease. In: Stein JH, Ed. Internal Medicine St Louis, MO: Mosby 1998; pp. 2233-2247.
56. Wolff RA, Abbruzzese JL, Evans DB. Neoplasms of the exocrine pancreas. In: Holland JF, Frei E, III, Eds. Cancer Medicine London: BC Decker Inc. 2000; pp. 1436-1464.
57. Vesely DL, Eichelbaum EJ, Sun Y, Alli AA, Vesely BA, Luther SL, et al. Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones. In Vivo 2007; 21: 445-452
58. Jemel A, Siegel R, Murray T, Xu J, Thun MJ. Cancer Statistics 2007. CA Cancer J Clin 2007; 55: 43-66.
59. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543
60. Vesely DL, Vesely BA, Eichelbaum EJ, Sun Y, Alii AA, Gower WR, Jr. Four cardiac hormones eliminate up to two-thirds of human breast cancers in athymic mice. In Vivo 2007; 21: 973-978
61. Jemel A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer Statistics, 2008. CA Cancer J Clin 2007; 57: 43-66.
62. th ed. Hamilton, Ontario: BC Decker Inc. 2003; pp. 1385-1445
63. nd ed. Philadelphia: W.B. Saunders Company 2001; pp. 260-287
64. Eichelbaum EJ, Sun Y, Alli AA, Gower Jr, WR, Vesely DL. Cardiac hormones and urodilatin eliminate up to 86% of human small-cell lung carcinomas in mice. Eur J Clin Invest 2008; 38: 562-570
65. Scholl FA, Dumesic PA, Khavari PA. Effects of active MEK 1 expression in vivo. Cancer Lett 2005; 230: 1-5.
66. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-1284
67. Sebolt-Leopold JS. Advances in the development of cancer therapeutics directed against the Ras mitogen-activated protein kinase pathway. Clin Can Res 2008; 14: 3651-3656
68. McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A, et al. Targeting the Raf/MEK/ERK pathway with smallmolecule inhibitors. Curr Opin Investig Drugs 2008; 9: 614-630
69. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004; 4: 937-947
70. Roberts PJ, Der CJ. Targeting the RAF-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26: 3291-3310
71. Sun Y, Eichelbaum EJ, Skelton WP, IV, Lenz A, Regales N, Wang H, et al. Vessel dilator and kaliuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res 2009; 29: 971-975
72. Sun Y, Eichelbaum EJ, Lenz A, Skelton WP, IV, Wang H, Vesely DL. Atrial natriuretic peptide and long-acting natriuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res 2009; 29: 1889-1893
73. Crews CM, Alessandrini A, Erikson RL. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 1992; 258: 478-480
74. Wu J, Harrison JK, Dent P, Lynch KR, Weber MJ, Sturgill TW. Identification and characterization of a new mammalian mitogenactivated protein kinase kinase MKK-2. Mol Cell Biol 1993; 13: 4539-4548
75. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 2007; 27: 1387-1392
76. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Atrial natriuretic peptide and long acting natriuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 2007; 27: 3813-3818
77. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-225
78. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-252
79. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Vessel dilator and kaliuretic peptide inhibit activation of ERK 1/2 in human prostate cancer cells. Anticancer Res 2006; 26: 3217-3222
80. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Atrial natriuretic peptide and long acting natriuretic peptide inhibit ERK 1/2 in prostate cancer cells. Anticancer Res 2006; 26: 4143-4148
81. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Insulin and epidermal growth factor activation of ERK 1/2 and DNA synthesis is inhibited by four cardiac hormones. J Cancer Mol 2007; 3: 113-120
82. Murthy KS, Teng B, Jin J, Makhlouf GM. G-protein-dependent activation of smooth muscle eNOS via natriuretic peptide clearance receptor. Am J Physiol 1998; 275: C1409-16.
83. Waldman SA, Rapoport RM, Murad FJ. Atrial natriuretic factor selectively activates membranous guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem 1984; 259: 14332-14334
84. Vesely DL. Signal transduction: activation of guanylate cyclasecyclic guanosine-3'-5' monophosphate system by hormones and free radicals. Am J Med Sci 1997; 314: 311-323
85. Saba SR, Garces AH, Clark LC, Gower WR, Jr, Vesely DL. Immunocytochemical localization of atrial natriuretic peptide, vessel dilator, long acting natriuretic peptide, and kaliuretic peptide in human pancreatic adenocarcinomas. J Histochem Cytochem 2005; 53: 989-995
86. Saba SR, Vesely DL. Cardiac natriuretic peptides: Hormones with anticancer effects that localize to nucleus, cytoplasm, endothelium and fibroblasts of human cancers. Histol Histopathol 2006; 21: 775-783
87. Dive V, Chang CF, Yiotakis A, Sturrock ED. Inhibition of zinc metallopeptidases in cardiovascular disease - from unity to trinity, or duality? Curr Pharm Des 2009; 15(31): 3606-3621
88. Nichols WW, Epstein BJ. Actions of selected cardiovascular hormones on arterial stiffness and wave reflections. Curr Pharm Des 2009; 15(3): 304-320
89. Zaiou M, Benachour H, Marteau JB, Visvikis-Siest S, Siest G. Genomics and the prospects of existing and emerging therapeutics for cardiovascular diseases. Curr Pharm Des 2009; 15(27): 3193-3206